456 Studies Now Enrolling
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
A study for patients with Idiopathic Parkinson's Disease using study drug CVT-301
| Sponsor: | Acorda Therapeutics |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAO4151 |
| U.S. Govt. ID: | NCT02240030 |
| Contact: | Amber Servi: 212-305-3665 / ads2178@columbia.edu |
Additional Study Information:
The purpose of this research is to find out whether an investigational drug called CVT-301, is helpful to people with Parkinson's Disease (PD). The treatment involves a new method for taking levodopa (LD) through an inhaler (which is like an asthma inhaler) to provide relief of motor fluctuations (OFF episodes), which are experienced by many Parkinson's disease patients.
This study is closed
